Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585815 · ClinicalTrials.gov registry record · Phase 1
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04585815 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 34 participants.
The verdict
NCT04585815, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Interventions
- DRUG Axitinib
- DRUG Binimetinib
- DRUG Encorafenib
- DRUG Sasanlimab
- DRUG Sasanlimab Prefilled syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-11-10 |
| Est. Completion | 2024-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04585815
The ClinicalTrials.gov registry entry for NCT04585815 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Axitinib is the first listed.
NCT04585815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04585815 about?
NCT04585815 is a clinical study titled "Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)". Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the...
What is the current status of trial NCT04585815?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-11-10. Estimated completion is 2024-10-29.
What interventions are being tested in trial NCT04585815?
The interventions under investigation include: Axitinib (DRUG), Binimetinib (DRUG), Encorafenib (DRUG), Sasanlimab (DRUG), Sasanlimab Prefilled syringe (DRUG).
Who is sponsoring clinical trial NCT04585815?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.